Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Gastrinoma
The approach to treatment often depends on the results of preoperative localization studies and findings at exploratory laparotomy. At exploration, 85% of these tumors are found in the gastrinoma triangle with 40% on the surface of the pancreas and 40% outside of the pancreas. Only 15% are found within the substance of the pancreas. Percutaneous transhepatic venous sampling may occasionally provide accurate localization of single sporadic gastrinomas. Resection (enucleation of individual tumors, if technically feasible), and even excision of liver metastases, is associated with long-term cure or disease control.Standard treatment options: Single lesion in head of the pancreas:[2,3,4,5]Enucleation.Parietal cell vagotomy and cimetidine.Total gastrectomy (rarely used with the advent of current therapies).Single or multiple lesions in the duodenum:[2,3,4,5]Pancreatoduodenectomy.Single lesion in body/tail of the pancreas:[2,3,4,5]Resection of body/tail.Multiple lesions in
Pancreatic Cancer Treatment (PDQ®): Treatment - Patient Information [NCI] - General Information About Pancreatic Cancer
Pancreatic cancer is a disease in which malignant (cancer) cells form in the tissues of the pancreas. The pancreas is a gland about 6 inches long that is shaped like a thin pear lying on its side. The wider end of the pancreas is called the head,the middle section is called the body,and the narrow end is called the tail. The pancreas lies behind the stomach and in front of the spine. The ...
Pancreatic Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Changes to This Summary (07 / 31 / 2014)
The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.This summary was reformatted.Stage I and Stage II Pancreatic Cancer TreatmentAdded text about a 5-year update of the Radiation Therapy Oncology Group (RTOG)-9704 trial, which reported that patients with pancreatic head tumors had a median survival and 5-year overall survival of 20.5 months and 22% survival rate with gemcitabine, versus 17.1 months and 18% with 5-fluorouracil. Also added text about a secondary analysis of RTOG-9704 that explored the correlation of adherence to protocol-specified radiation with patient outcomes. Added text to state that the European Organization for the Research and Treatment of Cancer/U.S. Gastrointestinal Intergroup (RTOG-0848) phase III adjuvant trial evaluating the impact of chemoradiation after completion of a full course of gemcitabine with or without
Pancreatic Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - General Information About Pancreatic Cancer
Related Summary Note: Another PDQ summary containing information related to pancreatic cancer includes: Unusual Cancers of Childhood (pancreatic cancer in children) Statistics Note: Estimated new cases and deaths from pancreatic cancer in the United States in 2010:[ 1 ] New cases: 43,140. Deaths: 36,800. Note: Some citations in the text of this section are followed by a level of evidence. The ...
Pancreatic Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Get More Information From NCI
Call 1-800-4-CANCERFor more information, U.S. residents may call the National Cancer Institute's (NCI's) Cancer Information Service toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from 8:00 a.m. to 8:00 p.m., Eastern Time. A trained Cancer Information Specialist is available to answer your questions.Chat online The NCI's LiveHelp® online chat service provides Internet users with the ability to chat online with an Information Specialist. The service is available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through Friday. Information Specialists can help Internet users find information on NCI Web sites and answer questions about cancer. Write to usFor more information from the NCI, please write to this address:NCI Public Inquiries Office9609 Medical Center Dr. Room 2E532 MSC 9760Bethesda, MD 20892-9760Search the NCI Web siteThe NCI Web site provides online access to information on cancer, clinical trials, and other Web sites and organizations that offer support
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Cellular Classification of Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
Table 1. Endocrine Tumors of the PancreasIslet CellsSecreted Active AgentTumor and SyndromeACTH = adrenocorticotropin; MSH = melanocyte-stimulating hormone; VIP = vasoactive intestinal peptide; WDHA = watery diarrhea, hypokalemia, and achlorhydria; 5-HT = serotonin.AlphaGlucagonGlucagonoma (diabetes, dermatitis)BetaInsulinInsulinoma (hypoglycemia)DeltaSomatostatinSomatostatinoma (mild diabetes); diarrhea/steatorrhea; gallstonesDGastrinGastrinoma (peptic ulcer disease)A -> DVIP and/or other undefined mediatorsWDHA5-HTACTHMSHCarcinoidCushing syndromeHyperpigmentationInteracinar CellsSecreted Active AgentTumor and SyndromeFPancreatic polypeptideMultiple hormonal syndromesEC5-HTCarcinoid
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Stage Information for Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
Note: The American Joint Committee on Cancer has published the 7th edition of the AJCC Cancer Staging Manual, which for the first time incorporates pancreatic neuroendocrine tumors in the same staging system as pancreatic exocrine tumors. The classification of these tumors as benign versus malignant is not always consistent, so the AJCC recommends that all pancreatic neuroendocrine tumors be staged using this system and reported to cancer registries. It also recommends that the protocol developed by the College of American Pathologists for endocrine pancreatic tumors be used to examine and stage specimens.Definitions of TNMThe American Joint Committee on Cancer has designated staging by TNM classification to define pancreatic neuroendocrine tumors (islet cell tumors).Table 2. Primary Tumor (T)aa Reprinted with permission from AJCC: Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer,
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Treatment - Patient Information [NCI] - Recurrent Pancreatic Neuroendocrine Tumors
Recurrent pancreatic neuroendocrine tumors (NETs) are tumors that have recurred (come back) after being treated. The tumors may come back in the pancreas or in other parts of the body.
Pancreatic Neuroendocrine Tumors (Islet Cell Tumors) Treatment (PDQ®): Treatment - Patient Information [NCI] - To Learn More About Pancreatic Neuroendocrine Tumors (Islet Cell Tumors)
For more information from the National Cancer Institute about pancreatic neuroendocrine tumors (NETs), see the following:Pancreatic Cancer Home PageUnderstanding Cancer Series: Targeted Therapies (Advances in Targeted Therapies)Targeted Cancer TherapiesFor general cancer information and other resources from the National Cancer Institute, see the following:What You Need to Know About™ CancerUnderstanding Cancer Series: CancerCancer StagingChemotherapy and You: Support for People With CancerRadiation Therapy and You: Support for People With CancerCoping with Cancer: Supportive and Palliative CareQuestions to Ask Your Doctor About CancerCancer LibraryInformation For Survivors/Caregivers/Advocates
Pancreatic Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - About This PDQ Summary
Purpose of This SummaryThis PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of pancreatic cancer. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.Reviewers and UpdatesThis summary is reviewed regularly and updated as necessary by the PDQ Adult Treatment Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH). Board members review recently published articles each month to determine whether an article should:be discussed at a meeting,be cited with text, orreplace or update an existing article that is already cited.Changes to the summaries are made through a consensus process in